The first-ever multi-drug trial to evaluate the effectiveness and safety of drugs used in the treatment of Ebola patients is underway.
The Ministry of Health of the Democratic Republic of the Congo (DRC) announced this week that a randomised controlled trial of four experimental therapies (mAb114, REGN-EB3, remdesivir and ZMapp) has commenced.
Up until now, more than 160 patients have been treated with the investigational therapeutics under the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework.
“While our focus remains on bringing this outbreak to an end, the launch of the randomised control trial in DRC is an important step towards finally finding an Ebola treatment that will save lives,” said World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus. “Until now, patients have been treated under a compassionate use protocol, with drugs that showed promise and had a good safety profile in laboratory conditions. The giant step DRC is taking now will bring clarity about what works best, and save many lives in years to come. We hope to one day say that the death and suffering from Ebola is behind us.”